Cheryl Guttman Krader
Multispecialty collaboration
Collaboration with specialists in other fields can improve outcomes for patients with skin cancer, and it can be personally and professionally rewarding for the dermatologist, according to one expert.
Building on cyclosporine for dry eye
A phase II study investigating a novel topical cyclosporine product (CyclASol, Novaliq) formulated in a semifluorinated alkane (SFA) vehicle showed promising efficacy, safety, and tolerability. Planning is ongoing for the phase III trial of cyclosporine in the SFA technology.
Teledermatology viable for skin cancer diagnosis
Teledermatology may play a role in skin cancer diagnsosis, an accumulating body of literature indicates, says one dermatologist.
Anti-PDGF inhibitor development continues despite negative results
Despite the failure of 2 clinical trials involving a combination therapy of platelet-derived growth factor (PDGF) inhibitor and anti-vascular endothelial growth factor (anti-VEGF) therapy, a third phase III study continues.
5-year CATT analysis finds anti-VEGF drugs a long-term AMD therapy
After 5 years of follow-up in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), the visual acuity gains achieved during the first 2 years of anti-VEGF treatment were not maintained, the choroidal neovascular lesions continued to evolve with evidence of persistent activity in some eyes, and there was increased retinal thinning and geographic atrophy (GA).
Selective techniques revolutionize treatment for retinoblastoma
Advancements in retinoblastoma have occurred in the areas of treatment, genetic testing, and diagnostic imaging.
Endoillumination growth amplifies tissue visualization
Endoillumination for vitreoretinal surgery continues to improve with the introduction of brighter, safer light sources with color filters that may allow opportunities for better tissue visualization.
Access, costs of bevacizumab key factors for DME therapy
The efficacy of intravitreal bevacizumab (Avastin, Genentech) for improving vision in patients with center-involving diabetic macular edema (DME) has been demonstrated in several clinical trials.
Data clearly demonstrates bevacizumab’s inferiority for DME
All three anti-vascular endothelial growth factor (anti-VEGF) agents that are commercially available have demonstrated efficacy for the treatment of diabetic macular edema (DME). However, it is clear from the results of clinical trials that outcomes with bevacizumab are not as good as those obtained using ranibizumab or aflibercept, according to Jean-François Korobelnik, MD.
Urethral lift: 5-year data point to procedure’s durability
Analyses of data from 5 years of prospective follow-up in the pivotal trial supporting regulatory approval of the prostatic urethral lift ([PUL] UroLift System, NeoTract) show that the minimally invasive procedure remains safe and provides rapid and durable benefits for men with symptomatic BPH.
var script= ' ';